Human cytomegalovirus (HCMV) is one of the main causes of serious complications in
immunocompromised patients and after congenital infection. There are currently drugs …

Cytomegalovirus (CMV) infection is a common complication in immunocompromised
patients, especially after hematopoietic stem cell or solid organ transplantation. Therapeutic …

Cytomegalovirus (CMV) infections may increase morbidity and mortality in
immunocompromised patients. Until recently, standard antiviral drugs against CMV were …

The prevention and treatment of human cytomegalovirus (HCMV) infections is based on the
use of antiviral agents that currently target the viral DNA polymerase and that may cause …

Introduction: Human cytomegalovirus (HCMV) is a major contributor of morbidity and
mortality, and its management is essential for the successful outcome of solid organ and …

This editorial summarizes recent developments in the management of ganciclovir-resistant
human cytomegalovirus (HCMV) infections. All current drugs available for systemic …

Purpose of Review Cytomegalovirus (CMV) infections are a common complication in solid
organ (SOT) and hematopoietic stem cell transplant (HSCT) recipients, leading to increased …

Introduction: Allogeneic hematopoietic cell transplants (allo-HCT) recipients are at the high-
risk of reactivation of cytomegalovirus (CMV), and reactivation is associated with significant …

Cytomegalovirus (CMV) infection is one of the most important infectious complications of
solid-organ transplantation, a serious, life-threatining, opportunistic pathogen in HIV-infected …

Human cytomegalovirus (HCMV) is ubiquitous worldwide and elicits global health problems.
The diseases associated with HCMV are a serious threat to humans, especially for the sick …